拉米呋啶对HBV DNA阳性肺结核患者肝功能干预的作用

Effect of lamivudine on the liver function of tuberculosis patients positive for HBV DNA

目的探讨拉米呋啶(LMV)对HBVDNA阳性肺结核患者肝功能干预作用。方法将100例HBV DNA阳性肺结核患者随机分成治疗组42例和对照组58例。观察两组病例肝损发生率,发生时间,损伤程度和完成抗结核疗程时间、乙肝病毒标志物的变化,并将所得数据作统计学处理。结果治疗组肝损发生率低(11.9%),出现时间晚(90～150)d,肝损程度轻,恢复快(15±3.5)d,完成抗结核治疗时间相对较短(210±15.4)d;与对照组相比有显著性差异(P<0.01)。结论 LMV对HBV DNA阳性肺结核患者肝功能有明显干预作用,可显著降低结核药物对此类患者的肝损伤,值得推广。

Aim To explore the effect lamivudine （LMV） on the liver function of patients with HBV DNA positive pulmonary tuberculosis. Methods There 100 HBV DNA positive pulmonary tuberculosis patients were randomly divided into teatmant group consisted of 42 and control group cconsisted of 58. The liver injury incidence rate and time, degree, reviving normality time, course of anti-tuberctdosis treatment completed and the change of hepatitis B virus marker were investigated. Datas were statistically analysed. Results The liver injury incidence rate of treatment group was mild and lower （ 11.9% ） and the occurrence time was late（90-150）days , the recovery time was faster（ 15＋-3.5 ）days with a relatively short course of anti- tuberculosis treatment（210±15.4）days than the control group ,showing significant difference as compared with the control group （P〈0.01）. Conclusion LMV had the obvious intervention effect on liver function of the patients with HBVDNA positive pulmonary tuberculosis. It can signiflcandy reduce the injury to the liver function by anti-turbereulosis drugs.